AB30 | 价格

AB30-1mg / 询价

Anti-CD19 Antibody (Denintuzumab Biosimilar)

产品信息(Product Info)
反应种属(Reactivities)

Human/Cynomolgus/Rhesus macaque

靶点(Target)

CD19

同型(Isotype)

Human IgG1-Kappa

标记(Conjugation)

Unconjugated

纯化(Purification)

protein A

无菌(Sterility)

0.2 μM filtered

制剂(Formulation)

PBS, 10% glycerol (pH 7.4)

内毒素(Endotoxin)

Less than 1 EU per μg by the LAL method.

稀释缓冲液
(Recommended Dilution Buffer)

PBS (pH 7.4), contains no stabilizers or preservatives.

纯度(Purity)

<p style="line-height: 25px;">> 95% as determined by Bis-Tris PAGE<br />> 95% as determined by HPLC</p>

存储(Storage)

<p style="line-height: 25px;">Valid for 12 months from date of receipt when stored at -80°C.<br />Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.</p>

应用(Applications)

ELISA

产品数据(Assay Data)
Bis-Tris PAGE
Denintuzumab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
SEC-HPLC
The purity of Denintuzumab Biosimilar is greater than 95% as determined by SEC-HPLC.
ELISA Data
Immobilized Human CD19, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Denintuzumab Biosimilar with the EC50 of 8.6ng/ml determined by ELISA. (QC Test)
背景(Background)

CD19 is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses. Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca2 stores.

文献(References)

Maude S L, Teachey D T, Porter D L, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia[J]. Blood, 2015, 125(26):4017-23.